WuXi AppTec expands site in California for pharmaceutical R&D services13 Dec 2018
Expanded facility will establish a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D including Phase I GMP manufacturing.
WuXi AppTec has announced the expansion of its facilities in San Diego, California.
WuXi AppTec's newly expanded facility will establish a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D including Phase I GMP manufacturing. The expansion will provide key elements of WuXi's small molecule capability and technology platform under one roof, further enhancing services to North American pharmaceutical and biotech industries. WuXi will also add extensively from the local talent base, further contributing to regional economic growth.
"Having a leading global organization like WuXi significantly invest in San Diego highlights the value of international partnerships, the county's place on the Pacific Rim and our region's long-standing support of the life sciences community," said San Diego County Supervisor Ron Roberts. "I especially applaud the company's vision that 'every drug can be made, and every disease can be treated."
"The San Diego life science community continues to thrive with the commitments and investments made by leading international powerhouses like WuXi AppTec," said Joe Panetta, president and CEO of Biocom. "Their latest facility expansion in San Diego is a testament to the deep relationships they have built with the local biotech community. Biocom applauds the positive impact they've had on the region's economic growth and innovative healthcare products for our patients."
"This expansion will enable us to better serve our U.S. and global customers, and contribute to the growth and success of the dynamic San Diego biotech ecosystem," said Dr. Ge Li, Chairman and CEO of WuXi AppTec. "Together with our ecosystem partners, we will continue to strengthen WuXi's capability and technology enabling platform to expedite the discovery and development of new medicines for patients worldwide, and for a future where every drug can be made and every disease can be treated."
HKBU scientists develop technique to eliminate drug side effects
19 May 2020
The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.Read more
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit
18 May 2020
CDMO is contracted to produce multiple clinical batches from German facilityRead more
Characterizing virus and virus-like particles
12 May 2020
New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.Read more
AI technology company launches with Novartis and Sarepta deals
11 May 2020
Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.Read more
Bio-Rad launches anti-certolizumab pegol antibodies
5 May 2020
Using this critical antibody reagent at the preclinical stage of development will minimize the need to revalidate assays with different reagents at the clinical development stage.Read more
BERG named visionary in first-ever Frost Radar AI in Drug Discovery report
13 Apr 2020
The biotech pioneer is one of the first companies to develop corporate partnerships in this application of artificial intelligence (AI) for drug discovery.Read more
AstraZeneca "incredibly excited" by lung cancer treatment trial
13 Apr 2020
Independent Data Monitoring Committee (IDMC) recommends unblind Phase III trial of Tagrisso 2 years ahead of schedule.Read more
German pharma companies are meeting the corona "stress test"
7 Apr 2020
The head of the leading German pharmaceutical industry organization says German firms are working top-speed to find coronavirus medications.Read more
World’s leading biobanks join a global network to advance personalized healthcare research
6 Apr 2020
The platform enables collaboration between pharmaceutical institutions, healthcare and academic researchers to generate valuable insights and advance medical research.Read more
Servier strengthens its R&D pipeline with Symphogen acquisition
6 Apr 2020
Symphogen becomes the antibody center of excellence within Servier.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation